Michael G. Goggins

Michael Goggins is a preeminent authority on pancreatic cancer early detection, biomarker development, familial pancreatic cancer, and pancreatic cyst surveillance at Johns Hopkins University School of Medicine. He directs the Multidisciplinary Pancreatic Cancer Early Detection Program and leads one of the world's most productive research programs dedicated to identifying pancreatic cancer at its earliest, curable stages. Goggins' laboratory has been at the forefront of identifying molecular biomarkers in biological fluids that can detect pancreatic cancer before symptoms develop. A major contribution has been the investigation of KRAS mutations and other somatic alterations in pancreatic juice — the fluid secreted by the pancreatic ductal system and collected during endoscopic retrograde cholangiopancreatography (ERCP). His group demonstrated that KRAS mutations are detectable in pancreatic juice from patients with pancreatic cancer and high-grade PanIN lesions, establishing pancreatic juice as a rich source of shed tumor DNA for early neoplasia detection. They later developed more comprehensive pancreatic juice DNA sequencing approaches capable of distinguishing benign from malignant pancreatic cysts. Goggins has extensively investigated CA 19-9 — the most widely used clinical biomarker for pancreatic cancer — characterizing its limitations for early detection (inadequate sensitivity and specificity in asymptomatic populations), and searching for improved biomarker panels. His laboratory has developed multivariate serum biomarker models combining CA 19-9 with additional proteins and metabolites to improve early detection sensitivity in high-risk individuals. Familial pancreatic cancer is another domain of Goggins' expertise. He helped establish the National Familial Pancreatic Tumor Registry (NFPTR) at Johns Hopkins, which has enrolled thousands of families with hereditary susceptibility to pancreatic cancer. His work has characterized the germline genetic architecture of familial PDAC — including BRCA2, PALB2, ATM, CDKN2A mutations — and developed evidence-based surveillance protocols for high-risk individuals using endoscopic ultrasound (EUS) and MRI/MRCP. Through the Cancer of the Pancreas Screening (CAPS) consortium studies, Goggins has defined the yield of surveillance endoscopy in high-risk individuals, demonstrating that systematic surveillance in defined high-risk populations (those with strong family history or germline mutations) can detect pancreatic neoplasms at surgically resectable stages, including high-grade precursor lesions.

Michael Goggins 是约翰斯·霍普金斯大学医学院胰腺癌早期检测、生物标志物开发、家族性胰腺癌和胰腺囊肿监测方面的权威专家。他领导的多学科胰腺癌早期检测项目是世界上最多产的早期检测研究项目之一。 Goggins 的实验室证明KRAS突变可在胰腺癌和高级别PanIN患者的胰液中检测到，建立了胰液作为早期肿瘤检测生物来源的重要地位。他对CA 19-9局限性的深入研究推动了多变量血清生物标志物组合模型的开发。他还帮助建立了约翰斯·霍普金斯家族性胰腺肿瘤登记处，并通过CAPS研究制定了高风险人群的内镜监测规程。